financingFresh money for Carbios Carbios SAS has announced a capital increase of around €122m that may grow up to €141m. more ➔
DigitisationSmarter, faster, cheaper: Veeva shows how This year’s Veeva R&D and Quality Summit in Madrid, accentuated the current trends and needs of the pharma and life sciences industries. more ➔
partnershipSanthera licences vamorolone rights to Cat... Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc. more ➔
CGTBioSenic halts ALLOB developmentBioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB. more ➔
M&ANeogap fully takes over TCER Oncology shar...Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders. more ➔
InfectionAntibody provides broad protection vs hant...An international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses. more ➔
Spin-outSyncona launches new gene therapy company...Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing. more ➔
AntibodyRoche to file MAA for eculizumab competito...Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany. more ➔
CGT CGT Catapult expanding with Scotch facilit...The world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh. more ➔
CGTBayer AG is joining forces with Acuitas Th...Bayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc. more ➔
